HER2-CAR constructs were comprised of either CD28 or 4-1BB domains and demonstrated functional activity in vitro, as documented by the assessment of cytokine production, T-cell proliferation, and cytotoxicity against breast cancer cell line [128]. This evidence concerns the gene ERBB2 and breast cancer.